Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Receivables - Other (2021 - 2025)

Historic Receivables - Other for Vistagen Therapeutics (VTGN) over the last 5 years, with Q4 2025 value amounting to $74000.0.

  • Vistagen Therapeutics' Receivables - Other fell 5033.56% to $74000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $74000.0, marking a year-over-year decrease of 5033.56%. This contributed to the annual value of $130000.0 for FY2025, which is 3627.45% down from last year.
  • Vistagen Therapeutics' Receivables - Other amounted to $74000.0 in Q4 2025, which was down 5033.56% from $92000.0 recorded in Q3 2025.
  • Vistagen Therapeutics' Receivables - Other's 5-year high stood at $380000.0 during Q2 2023, with a 5-year trough of $40600.0 in Q1 2021.
  • Moreover, its 5-year median value for Receivables - Other was $167000.0 (2024), whereas its average is $168513.3.
  • Per our database at Business Quant, Vistagen Therapeutics' Receivables - Other skyrocketed by 39261.08% in 2022 and then plummeted by 5105.26% in 2024.
  • Vistagen Therapeutics' Receivables - Other (Quarter) stood at $44000.0 in 2021, then surged by 354.55% to $200000.0 in 2022, then increased by 11.6% to $223200.0 in 2023, then crashed by 33.24% to $149000.0 in 2024, then crashed by 50.34% to $74000.0 in 2025.
  • Its Receivables - Other stands at $74000.0 for Q4 2025, versus $92000.0 for Q3 2025 and $111000.0 for Q2 2025.